Literature DB >> 12470525

Successful ICSI in a case of severe asthenozoospermia due to 93% non-specific axonemal alterations and 90% abnormal or absent mitochondrial sheaths.

A Alosilla Fonttis1, R Napolitano, M A Tomás.   

Abstract

The use of IVF and intracytoplasmic sperm injection (ICSI) to treat male infertility due to severe asthenozoospermia in cases of electron microscopically confirmed axonemal abnormalities has been reported. However, even with these sophisticated technologies, very few pregnancies and births have been achieved with ejaculated spermatozoa in infertility due to this condition. The existence of sperm-derived defects preclude normal embryo development, and another reason for low success rates may be that the most commonly used method for selecting viable spermatozoa for ICSI is sperm motility, which is absent in affected men. Consequently, the likelihood of selecting non-viable spermatozoa for ICSI is higher in these cases. This report describes a case of a pregnancy achieved by ICSI with ejaculated spermatozoa containing 93% non-specific axonemal alterations and 90% abnormal or absent mitochondrial sheaths. A total of 14 oocytes was obtained from the 31-year-old patient in her first IVF treatment cycle. Three of the 13 matured (metaphase II) oocytes were inseminated conventionally, and the other 10 metaphase II oocytes were submitted to ICSI. None of the oocytes inseminated conventionally were fertilized. Of the 10 oocytes submitted to ICSI, four zygotes and cleavage embryos resulted. Three embryos were transferred on day 3, and a successful pregnancy was achieved. One gestational sac, together with regular heart activity, was recorded by ultrasonography at 8 weeks of gestation. A pregnancy is currently ongoing.

Entities:  

Mesh:

Year:  2002        PMID: 12470525     DOI: 10.1016/s1472-6483(10)61831-7

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  7 in total

Review 1.  The sperm centrioles.

Authors:  Tomer Avidor-Reiss; Alexa Carr; Emily Lillian Fishman
Journal:  Mol Cell Endocrinol       Date:  2020-08-15       Impact factor: 4.102

2.  Successful twin birth following blastocyst culture of embryos derived from the immotile ejaculated spermatozoa from a patient with primary ciliary dyskinesia: a case report.

Authors:  Richard J Kordus; Robert L Price; Jeffrey M Davis; Gail F Whitman-Elia
Journal:  J Assist Reprod Genet       Date:  2008-10-15       Impact factor: 3.412

3.  Fluorescence-Based Ratiometric Analysis of Sperm Centrioles (FRAC) Finds Patient Age and Sperm Morphology Are Associated With Centriole Quality.

Authors:  Katerina A Turner; Emily L Fishman; Mariam Asadullah; Brooke Ott; Patrick Dusza; Tariq A Shah; Puneet Sindhwani; Nagalakshmi Nadiminty; Emanuela Molinari; Pasquale Patrizio; Barbara S Saltzman; Tomer Avidor-Reiss
Journal:  Front Cell Dev Biol       Date:  2021-04-22

Review 4.  The Role of Sperm Centrioles in Human Reproduction - The Known and the Unknown.

Authors:  Tomer Avidor-Reiss; Matthew Mazur; Emily L Fishman; Puneet Sindhwani
Journal:  Front Cell Dev Biol       Date:  2019-10-01

5.  Effect of polyvinylpyrrolidone on sperm function and early embryonic development following intracytoplasmic sperm injection in human assisted reproduction.

Authors:  Yoku Kato; Yoshikazu Nagao
Journal:  Reprod Med Biol       Date:  2012-04-10

6.  Compound Heterozygous Variants in the Coiled-Coil Domain Containing 40 Gene in a Chinese Family with Primary Ciliary Dyskinesia Cause Extreme Phenotypic Diversity in Cilia Ultrastructure.

Authors:  Lin Yang; Santasree Banerjee; Jie Cao; Xiaohong Bai; Zhijun Peng; Haixia Chen; Hui Huang; Peng Han; Shunyu Feng; Na Yi; Xueru Song; Jing Wu
Journal:  Front Genet       Date:  2018-02-02       Impact factor: 4.599

7.  CircRNA Role and circRNA-Dependent Network (ceRNET) in Asthenozoospermia.

Authors:  Francesco Manfrevola; Teresa Chioccarelli; Gilda Cobellis; Silvia Fasano; Bruno Ferraro; Carolina Sellitto; Giovanni Marella; Riccardo Pierantoni; Rosanna Chianese
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-10       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.